{"id":18431,"date":"2022-01-20T08:39:22","date_gmt":"2022-01-20T16:39:22","guid":{"rendered":"https:\/\/marketdepth.com\/?p=18431"},"modified":"2022-01-20T08:39:23","modified_gmt":"2022-01-20T16:39:23","slug":"valneva-vaccine-candidate-shows-to-neutralize-omicron-variant","status":"publish","type":"post","link":"https:\/\/marketdepth.com\/valneva-vaccine-candidate-shows-to-neutralize-omicron-variant\/","title":{"rendered":"Valneva Vaccine Candidate Shows to Neutralize Omicron Variant"},"content":{"rendered":"\n
Valneva SE<\/strong> (NASDAQ: VALN), a specialty vaccine company, announced Thursday results from an initial laboratory study demonstrating that serum antibodies induced by three doses of Valneva\u2019s inactivated COVID-19 vaccine candidate, VLA2001, neutralize the Omicron variant.<\/p>\n\n\n\n According to the data, Sera from 30 participants in the Phase 1\/2 trial VLA2001-201 were used in a pseudovirus assay to analyze neutralization of the ancestral SARS-CoV-2 virus as well as the Delta and Omicron variants. The results indicate that all 30 samples (100%) presented neutralizing antibodies against the ancestral virus and Delta variant, and 26 samples (87%) presented neutralizing antibodies against the Omicron variant. The mean fold reduction of neutralization relative to the ancestral virus was 2.7-fold for Delta and 16.7-fold for Omicron.<\/p>\n\n\n\n \u201cWe are extremely pleased with these results, which confirm the potential for broad-spectrum protection of our inactivated, adjuvanted whole virus vaccine and its ability to address currently circulating variants of concern. These results add to earlier findings from our Cov-Compare Phase 3 trial, in which two doses of VLA2001 given as a primary vaccination were shown to induce superior neutralizing antibody levels and a broad T-cell response. We continue to believe that VLA2001 could be an important component of the fight against COVID-19, and Valneva remains fully committed to bringing VLA2001 to people who need it as soon as we can.\u201d<\/p>Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva<\/cite><\/blockquote>\n","protected":false},"excerpt":{"rendered":"Valneva SE (NASDAQ: VALN), a specialty vaccine company, announced Thursday results from an initial laboratory study demonstrating that serum antibodies induced by three doses of Valneva\u2019s inactivated COVID-19 vaccine candidate, VLA2001, neutralize the Omicron variant. 30 Participant Trial According to the data, Sera from 30 participants in the Phase 1\/2 trial VLA2001-201 were used in… View Article<\/a>","protected":false},"author":3,"featured_media":18208,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":0,"footnotes":""},"categories":[9,17,8,11,16],"tags":[],"acf":[],"yoast_head":"\n30 Participant Trial<\/h5>\n\n\n\n